MDbio, a supplement company founded by four board-certified physicians, has reached a milestone in which three of its products have been clinically-studied in 3,500 diverse Americans across several clinical studies. The three products tested in these respective populations were MDrelief, MDcalm, and MDsleep, which are formulated to support pain relief, mood, and sleep, respectively.
 
MDcalm significantly outperformed placebo in supporting mood and sleep meaures, according to a clinical study involving 1,461 U.S. adults.
 
MDsleep significantly outperformed placebo in reducing measures of sleep disturbance, anxiety, and stress in clinical studies involving 620 adults, and was associated with improvements to self-reported quality of life.
 
MDrelief was found to significantly reduce measures of pain interference and pain intensity in women below the age of 50, and in general populations, in clinical trials involving 1,160 U.S. adults.
 
All studies were double-blinded, randomized, placebo-controlled clinical trials conducted by Raidcle Science, a public benefit corporation supporting clinical wellness research.
 
“MDbio represents the future of evidence backed natural products that are proven to deliver benefits, earning the trust of consumers, retailers, and doctors alike,” said Jeff Chen, MD, co-founder and CEO of Radicle Science.
 
MDbio was founded by four Los Angeles physicians: Kiarash Michel, MD; Babak Larian, MD, FACS; Siamak Tabib, MD; and Kamran Jamshidinia, DPM, FACFAS. The physicians founded the brand in response to the significant side effects from existing pharmaceutical treatments experienced by their patients.
 
“Now consumers finally have natural clinically proven solutions for some of the body’s most prevalent destabilizers. These include pain, sleep, and anxiety which are also often intertwined and difficult to treat in isolation,” said Michel. “Physicians and clinicians now have a product line they can trust since clinical research is the only barometer that proves efficacy.”
 
According to MDbio, formulations in the supplements marketplace might include ingredients that underwent low-quality clinical studies in foreign countries where standards aren’t enforced as well as in the U.S. Additionally, relying on ingredient studies, rather than research on finished products, is something very few supplement brands do.
 
MDbio takes a poly-pharmacological approach to test complete formulations, and how each respective ingredient in a product works together, and only proceeds to human clinical studies after in-house research to support safety and tolerability.
 
The results of the MDsleep clinical trial were published in Nutrients, with more peer-reviewed publications underway for the company’s newest products and studies.